Global Tracleer Bosentan Market Size, Share and Trends Analysis Report, By Type (32 mg Tablet, 62.5 mg Tablet, and 125 mg Tablet ), By Application (Children and Adults ), Forecast (2022-2028)

The global Tracleer bosentan market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Tracleer bosentan drug is an endothelin receptor antagonist that helps to decrease blood pressure in the lungs and is also used to treat pulmonary arterial hypertension. This drug works by blocking the endothelin-1 that helps in lowering the blood pressure in the lungs and helps to improve the ability to exercise. The global Tracleer bosentan drug market is increasing due to the increasing prevalence of pulmonary arterial hypertension across the globe. According to National Organization for Rare Disorders, pulmonary arterial hypertension is 3-5 times more prevalent in females than males. The age group of the females diagnosed with pulmonary arterial hypertension is between 30-60 years. It has been estimated that one to two individual out of one million is diagnosed with pulmonary arterial hypertension in the US. Almost 500- 1000 new cases are registered every year in US and Europe who are diagnosed with pulmonary arterial hypertension. According to the American Journal of Physiology, it is estimated that almost 1% of the global population is already affected by pulmonary arterial hypertension. Additionally, the global Tracleer bosentan drug market is growing due to the increasing cases of cardiac and pulmonary disorder globally which in turn is boosting the growth of the Tracleer bosentan market. According to World Health Organization 2019, Chronic Obstructive Pulmonary Disease is considered the third leading cause of death globally causing 3.23 million deaths.

 

For instance, In June 2019, Teva Pharmaceutical Industries Ltd. announced their launch of the generic version of Tracleer bosentan tablets in the US market. It will be available in 62.5 mg and 125 mg variants in the US market. In September 207, US Food and Drug Administration approved the paediatric version of pulmonary arterial hypertension drug for children aged 3years and older. In June 2019, NATCO Pharma Ltd. announced their submission of abbreviated New Drug Application with Para IV certification with the U.S. Food and Drug Administration for the generic version of Tracleer bosentan tablets. It is available in a 32mg tablet variant for oral administration. In June 2019, Hikma Pharmaceuticals PLC announced their launch of Tracleer bosentan tablets in the global market in 62.5mg and 125mg variants.

 

Some major players in the market include Teva Pharmaceutical Industries Ltd., NATCO Pharma Ltd. , Johnson & Johnson Services, Inc. among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new drug launches, to stay competitive in the market. For instance, in April 2019, Lupin Ltd. announced their partnership with NATCO Pharma Ltd. after receiving USFDA approval for the manufacturing of generic version of Tracleer bosentan tablets 62.5 mg and 125 mg variant in the market.

 

Market Coverage

 

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Teva Pharmaceutical Industries Ltd., NATCO Pharma Ltd.,  Johnson & Johnson Services, Inc. among others.

 

Key questions addressed by the report

 

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Tracleer Bosentan Market Report by Segment

 

By Type

 

• 32 mg Tablet
• 5 mg Tablet
• 125 mg Tablet

By Indication

• Children
• Adults

Global Tracleer Bosentan Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa